{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05509881",
            "orgStudyIdInfo": {
                "id": "1668"
            },
            "organization": {
                "fullName": "University of California, Irvine",
                "class": "OTHER"
            },
            "briefTitle": "Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial",
            "officialTitle": "Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial",
            "acronym": "CONDOR",
            "therapeuticArea": [
                "Other"
            ],
            "study": "continuous-glucose-monitoring-in-dialysis-patients-to-overcome-dysglycemia-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-15",
            "studyFirstSubmitQcDate": "2022-08-16",
            "studyFirstPostDateStruct": {
                "date": "2022-08-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Connie Rhee",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "University of California, Irvine"
            },
            "leadSponsor": {
                "name": "University of California, Irvine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This randomized controlled trial will investigate whether use of continuous glucose monitoring (CGM) vs. usual care with self-monitored blood glucose 1) enhances glycemic control, 2) reduces hypoglycemia risk, and 3) improves quality of life, diabetes distress, and fear of hypoglycemia in hemodialysis patients with diabetes mellitus.",
            "detailedDescription": "This is a parallel, two-arm randomized controlled trial comparing real-time CGM using Dexcom devices vs. usual care (self-monitored blood glucose 4-times/day) among 122 in-center hemodialysis patients with diabetes mellitus over a 12-week period. Our primary objective will be to determine the effects of CGM vs. usual care on glycemic control, defined by percent (%) of time in target glucose range (70-180 mg/dl). Our main and exploratory secondary objectives will be to determine the effects of CGM on CGM-indices of hypoglycemia, blood-based glycemic markers (HbA1c, glycated albumin, fructosamine), and patient-reported outcomes (health-related quality of life, diabetes distress, hypoglycemia fear). We will also evaluate feasibility endpoints by measuring CGM compliance during the intervention period and success/ease of implementing CGM training sessions among patients."
        },
        "conditionsModule": {
            "conditions": [
                "Hemodialysis",
                "Diabete Mellitus",
                "Continuous Glucose Monitoring"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 122,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Continuous glucose monitoring (CGM) arm",
                    "type": "EXPERIMENTAL",
                    "description": "During the intervention period, patients in the CGM arm will undergo continuous real-time \"unblinded\" CGM using Dexcom CGM devices.",
                    "interventionNames": [
                        "Device: Continuous glucose monitoring (CGM)"
                    ]
                },
                {
                    "label": "Usual care arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.",
                    "interventionNames": [
                        "Device: Usual care (Self-monitored blood glucose)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Continuous glucose monitoring (CGM)",
                    "description": "Patients in the CGM arm will undergo continuous real-time \"unblinded\" CGM using Dexcom CGM devices.",
                    "armGroupLabels": [
                        "Continuous glucose monitoring (CGM) arm"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Usual care (Self-monitored blood glucose)",
                    "description": "Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.",
                    "armGroupLabels": [
                        "Usual care arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent (%) of time in target glucose range (70-180 mg/dl)",
                    "description": "Ascertained by continous glucose monitoring",
                    "timeFrame": "12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percent (%) of time spent in hypoglycemia (<70 mg/dl)",
                    "description": "Ascertained by continous glucose monitoring",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Percent (%) of time spent in relative hypoglycemia (<100 mg/dl)",
                    "description": "Ascertained by continous glucose monitoring",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Glycemic variability",
                    "description": "Ascertained by continous glucose monitoring",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Hemoglobin A1c level",
                    "description": "Ascertained by blood test",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Fructosamine level",
                    "description": "Ascertained by blood test",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Glycated albumin level",
                    "description": "Ascertained by blood test",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Short Form 36 Survey Physical Component Summary Score",
                    "description": "Ascertained by Short Form 36 Survey; Minimum-Maximum range is 0-100; Higher scores indicate better health-related quality of life",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Diabetes Distress Scale Survey Score",
                    "description": "Ascertained by Diabetes Distress Scale Survey; Minimum-Maximum range is 1-6; Higher scores indicate higher states of distress",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Hypoglycemia Fear",
                    "description": "Ascertained by Hypoglycemia Fear Survey II",
                    "timeFrame": "12 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Continuous glucose monitoring compliance during the intervention period",
                    "description": "CGM compliance will be ascertained by two metrics; 1) wearing the CGM device \u22656 days/week, and 2) % of time CGM is active, which is an automatically captured/reported metric on the Dexcom G6 device",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Participant feedback on continuous glucose monitoring training sessions",
                    "description": "Survey graded on a 5-point Likert scale; participants' qualitative feedback",
                    "timeFrame": "12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to provide written informed consent\n* Age \u226518 years old\n* End-stage kidney disease status receiving in-center hemodialysis \u22654 weeks\n* Type 1 or type 2 diabetes\n* Actively performing self-monitored blood glucose (SMBG) testing for \u22654 weeks\n* \u226570% compliance wearing continuous glucose monitoring (CGM) device during the pre-trial period\n\nExclusion Criteria:\n\n* Inability to provide informed consent or comply with the study protocol\n* Limited visual acuity\n* Inability to wear CGM device\n* Prior use of CGM\n* Active pregnancy or planning a pregnancy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Connie Rhee",
                    "role": "CONTACT",
                    "phone": "714-456-5142",
                    "email": "crhee1@uci.edu"
                },
                {
                    "name": "Kamyar Kalantar-Zadeh",
                    "role": "CONTACT",
                    "phone": "714-456-5142",
                    "email": "kkz@uci.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Connie Rhee",
                            "role": "CONTACT",
                            "phone": "312-420-8474",
                            "email": "crhee@uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34750332",
                    "type": "BACKGROUND",
                    "citation": "Rhee CM, Kalantar-Zadeh K, Tuttle KR. Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 Jan 1;31(1):72-81. doi: 10.1097/MNH.0000000000000756."
                },
                {
                    "pmid": "34378258",
                    "type": "BACKGROUND",
                    "citation": "Narasaki Y, Park E, You AS, Daza A, Peralta RA, Guerrero Y, Novoa A, Amin AN, Nguyen DV, Price D, Kalantar-Zadeh K, Rhee CM. Continuous glucose monitoring in an end-stage renal disease patient with diabetes receiving hemodialysis. Semin Dial. 2021 Sep;34(5):388-393. doi: 10.1111/sdi.13009. Epub 2021 Aug 10."
                },
                {
                    "pmid": "34140100",
                    "type": "BACKGROUND",
                    "citation": "Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease. Semin Nephrol. 2021 Mar;41(2):96-103. doi: 10.1016/j.semnephrol.2021.03.004."
                },
                {
                    "pmid": "30037725",
                    "type": "BACKGROUND",
                    "citation": "Rhee CM, Kovesdy CP, You AS, Sim JJ, Soohoo M, Streja E, Molnar MZ, Amin AN, Abbott K, Nguyen DV, Kalantar-Zadeh K. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. Am J Kidney Dis. 2018 Nov;72(5):701-710. doi: 10.1053/j.ajkd.2018.04.022. Epub 2018 Jul 20."
                },
                {
                    "pmid": "28592525",
                    "type": "BACKGROUND",
                    "citation": "Rhee CM, Kovesdy CP, Ravel VA, Streja E, Brunelli SM, Soohoo M, Sumida K, Molnar MZ, Brent GA, Nguyen DV, Kalantar-Zadeh K. Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes. Diabetes Care. 2017 Aug;40(8):1050-1057. doi: 10.2337/dc17-0110. Epub 2017 Jun 7."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabete Mellitus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}